Progressive Supranuclear Palsy-A Global Review.
| Title: | Progressive Supranuclear Palsy-A Global Review. |
|---|---|
| Authors: | Kukkle PL; Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.; Neupane R; Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.; Pantelyat A; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Wills AM; Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.; Jabbari E; UCL Queen Square Institute of Neurology, London, UK.; Dopper EGP; Department of Neurology and Alzheimer Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands.; Kovacs GG; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.; Hoglinger G; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.; Aiba I; National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.; Litvan I; Parkinson's Disease and Other Movement Disorders Center, University of California (UCSD), San Diego, California, USA.; Ganguly J; Institute of Neurosciences Kolkata, Kolkata, India.; Whitwell JL; Mayo Clinic, Rochester, Minnesota, USA.; Ma J; XuanWu hospital of Capital Medical University, Beijing, China.; Okeng'O K; Muhimbili National Hospital, Dar es Salaam, Tanzania.; Skakibara R; Neurology Clinic Tsudanuma & Dowakai Chiba Hospital, Chiba, Japan.; Forrest S; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.; Lorenzl S; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.; Zewde YZ; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.; Compta Y; Hospital de Clinic, University of Barcelona, Barcelona, Spain.; Morris HR; UCL Queen Square Institute of Neurology, London, UK. |
| Corporate Authors: | MDS‐PSP Study Group |
| Source: | Movement disorders clinical practice [Mov Disord Clin Pract] 2026 Mar; Vol. 13 (3), pp. 611-622. Date of Electronic Publication: 2025 Sep 03. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101630279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2330-1619 (Electronic) Linking ISSN: 23301619 NLM ISO Abbreviation: Mov Disord Clin Pract Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hoboken, NJ : Wiley, [2014]- |
| MeSH Terms: | Supranuclear Palsy, Progressive*/epidemiology ; Supranuclear Palsy, Progressive*/diagnosis ; Supranuclear Palsy, Progressive*/therapy ; Supranuclear Palsy, Progressive*/genetics; Humans ; Prevalence ; Risk Factors |
| Abstract: | Background: Progressive Supranuclear Palsy (PSP) is a rare and severe neurodegenerative tauopathy characterized by diverse clinical phenotypes, including Richardson's syndrome (PSP-RS), PSP-parkinsonism (PSP-P), PSP-progressive gait freezing (PSP-PGF), and PSP-corticobasal syndrome (PSP-CBS). Significant geographic variation exists in prevalence, clinical presentations, and prognosis.; Objectives: This global review aims to systematically evaluate the epidemiological variation, clinical phenotypes, diagnostic practices, and management strategies for PSP, focusing on regional disparities and identifying influencing genetic and environmental factors.; Methodology: A comprehensive literature search following PRISMA guidelines was conducted, analyzing studies reporting PSP epidemiology, phenotypes, diagnostic criteria, risk factors, treatments, and prognoses. Data were categorized into epidemiology, risk factors, clinical presentations, diagnosis, treatment accessibility, and outcomes, considering geographic variation.; Results: Global PSP prevalence ranges between 5-6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure. Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction. Prognosis significantly varies with subtype; PSP-RS shows rapid progression and shorter survival (5-7 years), whereas PSP-P has a milder clinical course (8-12 years). Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services. Diagnostic accuracy has improved with the adoption of MDS-PSP criteria, facilitating recognition of diverse phenotypes.; Conclusions: Regional disparities in PSP prevalence, phenotypic presentation, and healthcare accessibility underscore the importance of standardized diagnostic criteria, targeted genetic and environmental studies, and equitable healthcare strategies. Enhanced global collaboration is essential for improving PSP diagnosis, management, and patient outcomes worldwide.; (© 2025 International Parkinson and Movement Disorder Society.) |
| References: | Steele JC. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10(4):333. https://doi.org/10.1001/archneur.1964.00460160003001.; Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS clinical diagnostic criteria for PSP. Mov Disord 2017;32(6):853–864. https://doi.org/10.1002/mds.26987.; Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ Published online 2021;n71:n71. https://doi.org/10.1136/bmj.n71.; Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome): report of the NINDS‐SPSP international workshop*. Neurology 1996;47(1):1–9. https://doi.org/10.1212/WNL.47.1.1.; Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60(6):615–620. https://doi.org/10.1136/jnnp.60.6.615.; Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132(Pt 1):156–171. https://doi.org/10.1093/brain/awn291.; Golbe LI. The epidemiology of progressive supranuclear palsy. Handbook of Clinical Neurology. New York: Elsevier; 2008:457–459. https://doi.org/10.1016/S0072-9752(07)01242-089.; Lyons S, Trépel D, Lynch T, Walsh R, O'Dowd S. The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta‐analysis. J Neurol 2023;270(9):4451–4465. https://doi.org/10.1007/s00415-023-11,791-2.; Swallow DMA, Zheng CS, Counsell CE. Systematic review of prevalence studies of progressive supranuclear palsy and Corticobasal syndrome. Movement Disord Clin Pract 2022;9(5):604–613. https://doi.org/10.1002/mdc3.13489.; Prashanth L, Kumar H, Wadia P, Muthane U. The spectrum of movement disorders in tertiary care centers in India: a tale of three cities. Ann Indian Acad Neurol 2021;24(5):721–725. https://doi.org/10.4103/aian.AIAN_1257_20.; Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of Synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013;70(7):859–866. https://doi.org/10.1001/jamaneurol.2013.114.; Stang CD, Turcano P, Mielke MM, et al. Incidence and trends of progressive supranuclear palsy and Corticobasal syndrome: a population‐based study. JPD 2020;10(1):179–184. https://doi.org/10.3233/JPD-191744.; Nath U. The prevalence of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome) in the UK. Brain 2001;124(7):1438–1449. https://doi.org/10.1093/brain/124.7.1438.; Schrag A, Ben‐Shlomo Y, Quinn N. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross‐sectional study. Lancet 1999;354(9192):1771–1775. https://doi.org/10.1016/S0140-6736(99)04137-9.; Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 2004;19(10):1239–1240. https://doi.org/10.1002/mds.20149.; Takigawa H, Kitayama M, Wada‐Isoe K, Kowa H, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav 2016;6(12):e00557. https://doi.org/10.1002/brb3.557.; Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011;124(3):182–187. https://doi.org/10.1111/j.1600-0404.2010.01442.x.; Raju S, Shetty K, Sahoo L, et al. Progressive supranuclear palsy in India: past, present, and future. Ann Indian Acad Neurol 2025;28(1):17–25. https://doi.org/10.4103/aian.aian_515_24.; Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2014;34(6):555–570. https://doi.org/10.1111/neup.12143.; Driver‐Dunckley ED, Zhang N, Serrano GE, et al. Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J Neuropathol Exp Neurol 2023;82(5):438–451. https://doi.org/10.1093/jnen/nlad025.; Kovacs GG, Milenkovic I, Wöhrer A, et al. Non‐Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community‐based autopsy series. Acta Neuropathol 2013;126(3):365–384. https://doi.org/10.1007/s00401-013-1157-y.; Nath U, Ben‐Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60(6):910–916. https://doi.org/10.1212/01.WNL.0000052991.70149.68.; Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49(5):1284–1288. https://doi.org/10.1212/WNL.49.5.1284.; Balint B, Neo S, Magrinelli F, et al. Ethnic differences in atypical parkinsonism‐is south Asian PSP different? Mov Disord Clin Pract 2024;11(11):1355–1364. https://doi.org/10.1002/mdc3.14182.; Jabbari E, Holland N, Chelban V, et al. Diagnosis across the Spectrum of progressive supranuclear palsy and Corticobasal syndrome. JAMA Neurol 2020;77(3):377–387. https://doi.org/10.1001/jamaneurol.2019.4347.; Takigawa H, Hanajima R, Aiba I, et al. Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: clinical features of the first registered patients and short‐term follow‐up analysis. Clinical Parkinsonism & Related Disorders 2024;11:100279. https://doi.org/10.1016/j.prdoa.2024.100279.; Farrell K, Humphrey J, Chang T, et al. Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes. Nat Commun 2024;15(1):7880. https://doi.org/10.1038/s41467-024-52,025-x.; Evans W, Fung HC, Steele J, et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett 2004;369(3):183–185. https://doi.org/10.1016/j.neulet.2004.05.119.; Pedicone C, Weitzman SA, Renton AE, Goate AM. Unraveling the complex role of MAPT‐containing H1 and H2 haplotypes in neurodegenerative diseases. Mol Neurodegener 2024;19(1):43. https://doi.org/10.1186/s13024-024-00731-x.; Xiao X, Yang Q, Wen Y, et al. Genetics of progressive supranuclear palsy in a Chinese population. Neurobiol Dis 2022;172:105819. https://doi.org/10.1016/j.nbd.2022.105819.; Ng ASL, Tan AH, Tan YJ, et al. Identification of genetic variants in progressive supranuclear palsy in Southeast Asia. Mov Disord 2024;39(10):1829–1842. https://doi.org/10.1002/mds.29932.; Lim SY, Dy Closas AMF, Tan AH, et al. New insights from a multi‐ethnic Asian progressive supranuclear palsy cohort. Parkinsonism Relat Disord 2023;108:105296. https://doi.org/10.1016/j.parkreldis.2023.105296.; Caparros‐Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case–control study. Caribbean Parkinsonism Study Group Lancet 1999;354(9175):281–286. https://doi.org/10.1016/s0140-6736(98)10166-6.; Lannuzel A, Hoglinger GU, Verhaeghe S, et al. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 2007;130(3):816–827. https://doi.org/10.1093/brain/awl347.; Escobar‐Khondiker M, Höllerhage M, Muriel MP, et al. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 2007;27(29):7827–7837. https://doi.org/10.1523/JNEUROSCI.1644-07.2007.; Kaas B, Hillis AE, Pantelyat A. Progressive supranuclear palsy and pawpaw. Neur Clin Pract 2020;10(2):e17–e18. https://doi.org/10.1212/CPJ.0000000000000704.; Caparros‐Lefebvre D, Golbe LI, Deramecourt V, et al. A geographical cluster of progressive supranuclear palsy in northern France. Neurology 2015;85(15):1293–1300. https://doi.org/10.1212/WNL.0000000000001997.; Alquezar C, Felix JB, McCandlish E, et al. Heavy metals contaminating the environment of a progressive supranuclear palsy cluster induce tau accumulation and cell death in cultured neurons. Sci Rep 2020;10(1):569. https://doi.org/10.1038/s41598-019-56,930-w.; Litvan I, Lees PSJ, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case–control study. Mov Disord 2016;31(5):644–652. https://doi.org/10.1002/mds.26512.; Vidal JS, Vidailhet M, Derkinderen P, De Gaillarbois TD, Tzourio C, Alperovitch A. Risk factors for progressive supranuclear palsy: a case–control study in France. J Neurol Neurosurg Psychiatry 2009;80(11):1271–1274. https://doi.org/10.1136/jnnp.2008.149849.; Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU. Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 2021;12:637176. https://doi.org/10.3389/fneur.2021.637176.; Rabadia SV, Litvan I, Juncos J, et al. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 2019;66:166–170. https://doi.org/10.1016/j.parkreldis.2019.07.036.; Bayram E, Marras C, Standaert DG, et al. Progressive supranuclear palsy and statin use. Mov Disord 2020;35(7):1253–1257. https://doi.org/10.1002/mds.28038.; Park HK, Ilango SD, Litvan I. Environmental risk factors for progressive supranuclear palsy. JMD 2021;14(2):103–113. https://doi.org/10.14802/jmd.20173.; Williams DR, De Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP‐parkinsonism. Brain 2005;128(6):1247–1258. https://doi.org/10.1093/brain/awh488.; Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007;22(15):2235–2241. https://doi.org/10.1002/mds.21698.; Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy‐parkinsonism from Richardson's syndrome. Brain 2007;130(Pt 6):1566–1576. https://doi.org/10.1093/brain/awm104.; Imai H, Narabayashi H. Akinesia‐concerning 2 cases of pure akinesia. Adv Neurol Sci (Tokyo) 1974;18:787–794.; Imai H, Narabayashi H, Sakata E. “Pure akinesia” and the later added supranuclear ophthalmoplegia. Adv Neurol 1987;45:207–212.; Imai H, Nakamura T, Kondo T, Narabayashi H. Dopa‐unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP? Adv Neurol 1993;60:622–625.; Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014;29(14):1758–1766. https://doi.org/10.1002/mds.26054.; Painous C, Martí MJ, Simonet C, et al. Prediagnostic motor and non‐motor symptoms in progressive supranuclear palsy: the step‐back PSP study. Parkinsonism Relat Disord 2020;74:67–73. https://doi.org/10.1016/j.parkreldis.2020.03.003.; Kanazawa M, Shimohata T, Endo K, Koike R, Takahashi H, Nishizawa M. A serial MRI study in a patient with progressive supranuclear palsy with cerebellar ataxia. Parkinsonism Relat Disord 2012;18(5):677–679. https://doi.org/10.1016/j.parkreldis.2011.11.011.; Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord 2009;24(9):1312–1318. https://doi.org/10.1002/mds.22583.; Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord 2013;19(12):1149–1151. https://doi.org/10.1016/j.parkreldis.2013.07.019.; Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord 2016;31(5):760–762. https://doi.org/10.1002/mds.26618.; Takamatsu Y, Matsuda N, Aiba I. The combination of short‐step and wide‐based gait is a gait characteristic in progressive supranuclear palsy: a retrospective, cross‐sectional study. Eur Geriatr Med 2019;10(5):809–815. https://doi.org/10.1007/s41999-019-00211-2.; Mori H, Oda M, Komori T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol 2002;104(3):273–278. https://doi.org/10.1007/s00401-002-0555-3.; Mahale R, Krishnan S, Divya K, Jisha V, Kishore A. Subtypes of PSP and prognosis: a retrospective analysis. Ann Indian Acad Neurol 2021;24(1):56–62. https://doi.org/10.4103/aian.AIAN_611_20.; Pradhan S, Tandon R. Progressive supra‐nuclear palsy: frequency of cardinal extrapyramidal features at first presentation. Postgrad Med J 2015;91(1075):274–277. https://doi.org/10.1136/postgradmedj-2014-132,696.; Couto B, Di Luca DG, Antwi J, et al. Ethnic background and distribution of clinical phenotypes in patients with probable progressive supranuclear palsy. Parkinsonism Relat Disord 2024;123:106955. https://doi.org/10.1016/j.parkreldis.2024.106955.; Golbe LI, Ohman‐Strickland P, Beisser EB, Elghoul FT. A convenient prognostic tool and staging system for progressive supranuclear palsy. Mov Disord Clin Pract 2020;7(6):664–671. https://doi.org/10.1002/mdc3.13010.; Nasri A, Ben Djebara M, Sghaier I, et al. Atypical parkinsonian syndromes in a north African tertiary referral center. Brain Behav 2021;11(1):e01924. https://doi.org/10.1002/brb3.1924.; Nasri A, Sghaier I, Neji A, et al. Phenotypic Spectrum of progressive supranuclear palsy: clinical study and apolipoprotein E effect. JMD 2024;17(2):158–170. https://doi.org/10.14802/jmd.23178.; Hewer S, Varley S, Boxer AL, Paul E, Williams DR, AL‐108‐231 Investigators. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Mov Disord 2016;31(10):1574–1577. https://doi.org/10.1002/mds.26694.; Kukkle P, Gupta R, Desai S, et al. Pan India Registry for Progressive Supranuclear Palsy (PAIR‐PSP); In: 2022:Abstract‐1119. https://doi.org/10.1002/mds.29223.; Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017;32(7):995–1005. https://doi.org/10.1002/mds.27034.; Metta V, Chaudhuri KR, Leta V, et al. Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: a 1‐year follow‐up data report. Brain Behav 2022;12(9):e2547. https://doi.org/10.1002/brb3.2547.; Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: a consensus statement of the CurePSP centers of care. Front Neurol 2021;12:694872. https://doi.org/10.3389/fneur.2021.694872.; Matsuda N, Takamatsu Y, Aiba I. Effect of therapeutic exercise on the balance of patients with progressive supranuclear palsy: a pilot study. Front Neurol 2022;13:955893. https://doi.org/10.3389/fneur.2022.955893.; Matsuda N, Takamatsu Y, Sawada M, Aiba I. Performance of a Two‐Week Rehabilitation Improves Motor Function in Inpatients with Progressive Supranuclear Palsy: A Pre–Post Study. Brain Sci 2025;15(1):88. https://doi.org/10.3390/brainsci15010088.; Arena JE, Weigand SD, Whitwell JL, et al. Progressive supranuclear palsy: progression and survival. J Neurol 2016;263(2):380–389. https://doi.org/10.1007/s00415-015-7990-2.; Guasp M, Molina‐Porcel L, Painous C, et al. Association of PSP phenotypes with survival: a brain‐bank study. Parkinsonism Relat Disord 2021;84:77–81. https://doi.org/10.1016/j.parkreldis.2021.01.015.; Jabbari E, Woodside J, Tan MMX, et al. The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy. Mov Disord 2019;34(9):1307–1314. https://doi.org/10.1002/mds.27786. |
| Contributed Indexing: | Keywords: PSP study group; clinical profile; global comparison; progressive supranuclear palsy |
| Entry Date(s): | Date Created: 20250903 Date Completed: 20260317 Latest Revision: 20260403 |
| Update Code: | 20260403 |
| PubMed Central ID: | PMC13042570 |
| DOI: | 10.1002/mdc3.70338 |
| PMID: | 40898879 |
| Database: | MEDLINE |
Journal Article; Review